Conflicting clinical environment about the management of antithrombotic agents during the periendoscopic period in Japan

Background and Aims:  Although there are guidelines for the management of antithrombotic agents during the periendoscopic period, gaps between various guidelines create a confusing situation in daily clinical practice. The purpose of this study was to examine the current management of antithrombotic agents during the periendoscopic period in Japan.

[1]  N. Yamamichi,et al.  CONTROVERSY ON THE MANAGEMENT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS FOR SCHEDULED ENDOSCOPY , 2011, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[2]  B. Gage,et al.  Adverse events associated with anticoagulation therapy in the periendoscopic period. , 2010, Gastrointestinal endoscopy.

[3]  Michelle A. Anderson,et al.  Management of antithrombotic agents for endoscopic procedures. , 2009, Gastrointestinal endoscopy.

[4]  N. Yamamichi,et al.  Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy , 2009, Journal of Gastroenterology.

[5]  T. Gotoda,et al.  Multi‐center survey regarding the management of anticoagulation and antiplatelet therapy for endoscopic procedures in Japan , 2009, Journal of gastroenterology and hepatology.

[6]  D. Rockey,et al.  Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the West. , 2008, Gastrointestinal endoscopy.

[7]  A. Terashi,et al.  Antiplatelet Cilostazol Is Beneficial in Diabetic and/or Hypertensive Ischemic Stroke Patients , 2008, Cerebrovascular Diseases.

[8]  A. Gershlick,et al.  Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures , 2008, Gut.

[9]  J. Hallas,et al.  Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study , 2006, BMJ : British Medical Journal.

[10]  C. Samama,et al.  Guidelines of the French Society for Digestive Endoscopy (SFED) , 2006, Endoscopy.

[11]  R. Knill-Jones,et al.  Upper gastrointestinal mucosal abnormalities and blood loss complicating low‐dose aspirin and antithrombotic therapy , 2006, Alimentary pharmacology & therapeutics.

[12]  A. Munakata,et al.  Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures , 2005, Journal of Gastroenterology.

[13]  D. Faigel,et al.  ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. , 2005, Gastrointestinal endoscopy.

[14]  H. Diener,et al.  European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.

[15]  M. Rawlins,et al.  Prophylactic aspirin and risk of peptic ulcer bleeding , 1995, BMJ.

[16]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[17]  M. Laakso,et al.  The European Stroke Prevention Study , 1991, Neurology.

[18]  N. Talley.  Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding: A Randomized Trial , 2010 .

[19]  Biomed Programme.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009 .

[20]  Kiichi Sato,et al.  Management of anticoagulation and antiplatelet therapy in endoscopic procedures , 2008 .

[21]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[22]  J. Olsen,et al.  Risk of Upper Gastrointestinal Bleeding Associated With Use of Low-Dose Aspirin , 2000 .